Introduction
============

Patients with end-stage renal disease have a compromised immune system ([@B1]). Infection is a common complication and is the second leading cause of death in hemodialysis patients ([@B2]). Indeed, the risk of bacteremia in hemodialysis patients is 26-fold higher than in the general population ([@B3]).

Septic pulmonary embolism (SPE) is an uncommon disorder in which infected thrombi from a primary infectious site lead to infarctions in the pulmonary vasculature as well as focal abscesses. SPE has a mortality rate of 10-20% ([@B4], [@B5]). Historically, SPE was most commonly associated with right-sided infective endocarditis in intravenous drug users, or Lemierre\'s syndrome, and pelvic thrombophlebitis. However, recently, the incidence of SPE has been increasing in immunocompromised patients and patients using vascular catheters and implantable devices ([@B5], [@B6]).

Pneumothorax is a rare but life-threatening complication of SPE, as it sometimes occurs bilaterally. No cases of pneumothorax secondary to SPE have been reported in a long-term hemodialysis patient. We herein report a hemodialysis patient with psoas abscess caused by methicillin-resistant *Staphylococcus aureus* (MRSA) in whom pneumothorax occurred secondary to SPE.

Case Report
===========

A 62-year-old woman with end-stage renal disease due to glomerulonephritis had been undergoing hemodialysis for 13 years. She had received two nerve block injections for back pain caused by lumbar canal stenosis at one and two weeks (one injection each) before admission. As she presented with a fever and recent-onset confusion, she was transported by an ambulance to our hospital. Her body temperature was 39.5℃ (103.1°F) and her blood pressure was 65/48 mmHg, associated with tachycardia (117 beats/min), tachypnea (20/min), and hypoxia (PaO~2~ 80.1 mmHg on 2 L/min of oxygen).

A physical examination revealed that the patient\'s knees were swollen. An arteriovenous dialysis graft infection was not obvious. Her white blood cell count was 19,000 cells/mm^3^, with a marked left shift, and her platelet count was 48,000 cells/mm^3^. Laboratory data showed elevated levels of C-reactive protein, fibrinogen, fibrinogen-degradation products, and D-dimer (46.32 mg/dL, 876 mg/dL, 53.9 μg/mL, and \>30 μg/mL, respectively). The activated partial thromboplastin time was prolonged (50.8 s), but the prothrombin time was not prolonged.

Computed tomography (CT) revealed a right psoas abscess in addition to right piriformis, pectineus, obturator externus, adductor muscle, and splenic abscesses ([Fig. 1](#g001){ref-type="fig"}). Multiple septic pulmonary emboli in both lungs were also found on chest X-ray and chest CT ([Fig. 2A](#g002){ref-type="fig"}). There were no findings of brain abscesses on brain CT. Vegetation was also not observed on the heart valves by an echocardiograph. A diagnosis of psoas abscess with multiple abscesses, SPE, and septic shock was therefore made.

![Computed tomography (CT) findings. Abscesses were observed in the right psoas, from the higher level (A and B, arrow) to the lower level (C and D, white arrow), right piriformis (C, arrowhead), right pectineus (D, arrowhead), right obturator externus (D, black arrow), right adductor muscle (E, arrow), and spleen (F, arrow).](1349-7235-56-3243-g001){#g001}

![Time-course for the development of pulmonary septic emboli. Small septic emboli were observed on admission (A, arrows). The number and size of septic emboli increased in both lungs on the ninth day of hospitalization (B). The septic emboli resolved and the bullae remained in the right lung after four months of treatment (C).](1349-7235-56-3243-g002){#g002}

Meropenem was administered as the initial antibiotic treatment, and percutaneous drainage of the psoas abscess was performed. Later, cultures of blood, abscess content, and knee synovial fluid showed MRSA growth. The antibiotic treatment was changed to intravenous vancomycin on the third day of hospitalization. Her condition rapidly improved, and she recovered from septic shock. The psoas abscess markedly reduced, and blood cultures performed on the sixth day of hospitalization were negative. However, the multiple SPE lesions continued to increase and enlarge ([Fig. 2B](#g002){ref-type="fig"}), and right-sided pneumothorax occurred on the tenth day of hospitalization ([Fig. 3](#g003){ref-type="fig"}).

![Chest X-ray findings. Right-sided pneumothorax occurred on the tenth day of hospitalization.](1349-7235-56-3243-g003){#g003}

A chest tube was inserted for drainage of air, and the intravenous vancomycin treatment was continued. The pneumothorax resolved after 8 weeks, with all abscesses except for the splenic abscess and SPE resolving after 11 weeks of treatment ([Fig. 2C](#g002){ref-type="fig"}). However, the SPE lesions and splenic abscess showed a decreasing trend. As the patient refused the offered treatment of splenectomy, intravenous vancomycin treatment was continued. The SPE lesions disappeared 14 weeks after the commencement of treatment, and the splenic abscess resolved 2 weeks later. Intravenous vancomycin treatment was discontinued the following week. Neither the abscesses nor the SPE relapsed, and she was transferred to a rehabilitation hospital.

Discussion
==========

We described a case of a long-term hemodialysis patient with MRSA-related psoas abscess with multiple abscesses in other muscles and in the spleen, septic arthritis of the knees, and SPE. Pneumothorax occurred at a late stage as a consequence of the progression of SPE, even though the MRSA-related psoas abscess and septicemia had responded to the treatment with vancomycin and percutaneous drainage.

Long-term hemodialysis patients, as in this case, are immunocompromised patients and at a high risk for bloodstream infection. *Staphylococcus aureus*, including MRSA, is the most common causative organism ([@B2]). The patient received two nerve block injections before the development of the psoas abscess; therefore, in addition to the possibility of a bloodstream infection, MRSA infection may have resulted from the injections.

Pneumothorax secondary to SPE is rare, and only six cases have been reported within journals in English ([@B7]-[@B11]). We found two more case reports in Japanese ([@B12], [@B13]). We reviewed all of the previously reported cases, and the characteristics of these as well as our case are summarized in [Table](#t001){ref-type="table"}. Six of the patients were young intravenous drug abusers, and two were elderly immunocompromised patients. Cases of two immunocompromised patients were reported recently, which is compatible with the etiology of SPE showing an increasing incidence in immunocompromised patients. One elderly patient received hemodialysis therapy for rapidly progressive glomerulonephritis, but this was for a short period until the onset of SPE following the use of a central venous catheter. The present report is the first of pneumothorax secondary to SPE in a long-term hemodialysis patient with an arteriovenous fistula or graft.

###### 

Summary of Cases with Pneumothorax as a Complication of Septic Pulmonary Embolism.

  Reference                         \(7\)                            \(8\)                          \(9\) case 1                           \(9\) case 2                           \(10\)                           \(12\)                                                                               \(11\)                           \(13\)                           This case
  --------------------------------- -------------------------------- ------------------------------ -------------------------------------- -------------------------------------- -------------------------------- ------------------------------------------------------------------------------------ -------------------------------- -------------------------------- ------------------------------------------------------------------
  Patient age/sex                   19/male                          24/male                        23/male                                26/male                                23/male                          72/female                                                                            25/male                          66/male                          62/female
  Pathogen                          *Staphylococcus aureus* (MSSA)   *Staphylococcus aureus*        *Staphylococcus aureus* (MSSA)         *Staphylococcus epidermidis*           *Staphylococcus aureus* (MSSA)   *Staphylococcus aureus* (MRSA)                                                       *Staphylococcus aureus* (MSSA)   *Staphylococcus aureus* (MSSA)   *Staphylococcus aureus* (MRSA)
  Medical history                   intravenous drug user            intravenous drug user          intravenous drug user, HIV infection   intravenous drug user, HIV infection   intravenous drug user            rapidly progressive glomerulonephritis (hemodialysis, glucocorticosteroid therapy)   intravenous drug user            type 2 diabetes mellitus         end-stage renal disease due to glomerulonephritis (hemodialysis)
  Source of infection               tricuspid valve endocarditis     tricuspid valve endocarditis   tricuspid valve endocarditis           tricuspid valve endocarditis           tricuspid valve endocarditis     central venous catheter-related infections                                           pulmonary valve endocarditis     prostatic abscess                psoas abscess
  Time to onset after treatment\*   6 days                           5 days                         15 days                                within a day                           7 days                           13 days                                                                              same time                        13 days                          10 days
  Location of pneumothorax          bilateral                        right                          bilateral                              right                                  left                             right                                                                                left                             bilateral                        right
  Treatment period                  6 weeks                          N/A                            8 weeks                                4 weeks                                12 weeks                         7 weeks                                                                              N/A                              8 weeks                          17 weeks
  Outcome                           survival                         survival                       survival                               survival                               survival                         survival                                                                             survival                         dead                             survival

MSSA: Methicillin-sensitive *Staphylococcus aureus*, MRSA: Methicillin-resistant *Staphylococcus aureus*

\*Time to the onset of pneumothorax after the commencement of treatment for the primary infection.

Staphylococci were the infectious pathogens in all reported cases of secondary pneumothorax due to SPE, and eight of the nine cases were caused by *Staphylococcus aureus*. Methicillin-sensitive *Staphylococcus aureus* (MSSA) was identified in 5 cases and MRSA in 2 cases. *Staphylococcus aureus*, including MRSA, is also a predominant cause of SPE ([@B4], [@B5]). Pulmonary cavitation is a well-known manifestation in *Staphylococcus aureus* pneumonia ([@B14]), and pneumothorax is also a common complication of staphylococcal pneumonia ([@B15]). Community associated-MRSA is often associated with severe necrotizing pneumonia, which is characterized by pulmonary inflammation with consolidation, peripheral necrosis, and multiple small cavities. In the present case, several SPE lesions had progressed subpleurally, and subpleural pulmonary bullae were observed in the right lung after treatment. Coalescence of necrotic infarcts caused by MRSA might form large abscesses and involve the pleura, causing pneumothorax. Previous studies have reported infectious pleural effusion ([@B9], [@B12]), which may indicate that SPE lesions involve the pleura. However, pleural fluid culture was not performed in the present case.

In 6 previous cases ([@B1]-[@B10], [@B12], [@B13]), pneumothorax secondary to SPE occurred 5-15 days after hospitalization, despite appropriate treatment for the infection. Similarly, in the present case, although the septic shock and bacteremia were resolved by intravenous vancomycin treatment and percutaneous drainage of the psoas abscess, pneumothorax occurred 10 days after treatment. This time lag may be explained by the fact that infective thrombi were lodged in the lung capillaries. Therefore, vancomycin could not be delivered to the peripheral lung abscesses, which may have progressed, leading to the rupture of the pleura.

The treatment period of the present case was longer than in previous cases. This may be due to the treatment of the splenic abscess, which continued for the entire duration of this case. Splenic abscess is an uncommon infection with a high mortality rate. Robinson et al. reported that all infective endocarditis and splenic abscess patients who did not undergo splenectomy died, and half of these had undergone valvar replacement ([@B16]). Splenic abscess is usually managed by a combination of antibiotic therapy and splenectomy, but our patient did not wish to undergo splenectomy.

In conclusion, pneumothorax can occur following SPE in patients on long-term hemodialysis. These patients are immunocompromised hosts at a high risk of bloodstream infection, usually caused by *Staphylococcus aureus*. Furthermore, careful attention should be paid to the progression of SPE and the potential for late-onset pneumothorax, even in cases in which the primary infection is controlled.
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